Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013
Health Care Conference
SAN DIEGO, May 10, 2013
SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at the
Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The
presentation is scheduled for Wednesday, May 15^th at 1 p.m. Pacific Time. To
listen to the live webcast or a replay of the presentation, please visit the
Investor Relations section of the Company's Web site at www.orexigen.com. A
replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase 3 clinical trials and for which a New Drug Application has
been submitted and reviewed by the FDA. The Company has also reached agreement
with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the
Contrave cardiovascular outcomes trial. The Company's other product candidate,
Empatic™, has completed Phase 2 clinical trials. Further information about the
Company can be found at www.orexigen.com.
Orexigen Contact: Media Contact:
McDavid Stilwell Denise Powell
VP, Corporate Communications and Business Development BrewLife
(858) 875-8629 (510) 703-9491
SOURCE Orexigen Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.